Insulin pens were first introduced in 1987 and partially address quality of life and diabetes outcome-related barriers to insulin delivery with vial and syringe (including convenience, dosage, pain, and hypoglycemia) [73]. The gene discussed is INS; the disease is diabetes mellitus.